Magnesium Modulates Doxorubicin Activity through Drug Lysosomal Sequestration and Trafficking-Reference-Cited by-同舟云学术

Magnesium Modulates Doxorubicin Activity through Drug Lysosomal Sequestration and Trafficking

Published:2016-03-11 Issue:3 Volume:29 Page:317-322
ISSN:0893-228X
Container-title:Chemical Research in Toxicology
language:en
Short-container-title:Chem. Res. Toxicol.

Author:

Trapani Valentina¹,Luongo Francesca¹,Arduini Daniela¹,Wolf Federica I.¹

Affiliation:

1. Istituto di Patologia Generale, Facoltà di Medicina e Chirurgia “A. Gemelli”, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy

Funder

Ministero dell?Istruzione, dell?Universit? e della Ricerca

Tavola Valdese

Publisher

American Chemical Society (ACS)

Subject

Toxicology,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.chemrestox.5b00478

Reference15 articles.

1. Cell (patho)physiology of magnesium

2. Magnesium and tumors: Ally or foe?

3. From magnesium to magnesium transporters in cancer: TRPM7, a novel signature in tumour development

4. Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice

5. Magnesium homeostasis in colon carcinoma LoVo cells sensitive or resistant to doxorubicin

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does insulin make breast cancer cells resistant to doxorubicin toxicity?;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-05-25

2. Glasgow Magnesium Symposium 2022: Wrap up and depart;Magnesium Research;2022-04-01

3. EFFECT OF METAL IONS ON FUNCTIONING OF ANTIOXIDANT SYSTEM AND ENZYMES OF EXTRACELLULAR MATRIX IN TUMORS DIFFERED IN THEIR DOXORUBICIN SENSITIVITY;Fiziolohichnyĭ zhurnal;2020-08-20

4. Dysregulation of Mg2+ homeostasis contributes to acquisition of cancer hallmarks;Cell Calcium;2019-11

5. Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events;Molecular Case Studies;2017-04-27